Pharmacogenomics in Practice is an online course that was developed to teach health care providers how to optimize patient responses to prescription medications by using pharmacogenomic testing.
Pharmacogenomics in Practice was designed to educate lay professional audiences with no genetics background about implementing pharmacogenomic testing in the clinic. This course is for:
- Physicians, nurses and other health care providers in family/internal medicine
- Health care providers in specialty areas like psychiatry, cardiology, oncology, anesthesiology
- Health care providers in the concierge, functional and lifestyle medicine areas
- Genetic counselors who want more detailed information about pharmacogenomic resources
- Pharmacists who want to know which drugs have the most valid pharmacogenomic tests
- Diagnostic labs who want guidance developing pharmacogenomic product offerings
- Software companies developing tools to manage pharmacogenomic information
- Insurance companies who want to understand how to value pharmacogenomic tests
Learn how to implement and scale pharmacogenomic testing across your practice
Giving patients the best care possible means knowing about the latest tools and technologies for diagnosing and treating disease and being able to evaluate and use them in practice. A single pharmacogenomic test has the potential to improve treatment response in your patients through proper dosing and drug selection.
Molecular basis of drug response
Get a grasp on the concepts and vocabulary of pharmacogenomics to feel more confident when discussing testing with your colleagues or patients. Learn about genetic differences in drug metabolism; how common rapid or poor metabolizers are; what factors besides genetic variation impacts drug metabolism.
Pharmacogenomic information in the drug label
The drug label is a go-to source for prescribing a medication, but it’s not always easy to make sense of pharmacogenomic information in the drug label. Learn what information you can and can’t get from the drug label.
Clinical validity and utility of pharmacogenomics tests
There are many pharmacogenomic tests available, but it’s not always clear whether they are any good. Learn about the organizations that evaluate specific genes, the strength of evidence and recommendations to changes to prescribing behavior. Familiarize yourself with tools that you can access to evaluate specific pharmacogenomic tests for their validity and utility.
Paying for pharmacogenomics
Lack of insurance coverage can be a deterrent for ordering a pharmacogenomic test. Knowing why certain tests are covered can help you make informed choices about the value of testing in your patients. This section discusses cost-effectiveness studies and reviews tests already covered by insurance.
Which patients are candidates for pharmacogenomic testing
Pharmacogenomic testing may not be right for everybody, but being able to recognize which patients might benefit is the first step toward improving medication responses. We’ll walk through various case studies, identifying major categories of patients who could benefit from pharmacogenomic testing.
Choosing a pharmacogenomics laboratory and testWith so many laboratories and tests available, the decision about which one to use can be overwhelming. We’ll break down the key factors on which to judge a pharmacogenomic test, review sample test reports from major labs and learn how to navigate the results.
What our students are saying
“Loved Dr. McCarthy’s presentation content, style, delivery and demeanor.” — John Hoben, Principal, Hoben Associates
“Jeanette was incredible—making the complex seem so simple...such a gift! “— Jeff P, Concierge medicine physician
“Great presentation with a lot of data compressed that was clinically relevant and immediately applicable.” — Carrie B., Concierge medicine physician
About the course
Pharmacogenomics in Practice consists of the following:
- Seven on-demand course videos (total watch time ~2 hour)
- Hands-on exercises
- An active discussion forum with other Pharmacogenomics in Practice students and faculty
- Patient resources: brochure for your patients; talking points for communicating with patients
- Whitepaper: analysis of currently marketed pharmacogenomic tests
- Whitepaper: FDA regulation of pharmacogenomis
- 20% discount on Precision Medicine: A Guide to Genomics in Clinical Practice
- Certification of completion upon passing a short quiz
Please note: We recommend that students taking the Pharmacogenomics in Practice course have a basic understanding of human genetics before enrolling. If you don’t have a background in genetics— or if you want a quick refresher— we offer a free, 30-minute online course, PM101: Human Genomics.
This course is available for a one-time fee of $295.
The information provided through this course is for educational purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient's medical condition.
All materials are copyrighted. Republication or redistribution of PMA content is prohibited without prior written consent. PMA shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.
Jeanette McCarthy has been a leading educator in the field of precision medicine for over a decade. She’s designed and delivered dozens of online courses and in-person workshops to healthcare providers, consumers, diagnostic companies, health IT companies, investors and others worldwide.
Dr. McCarthy spent the early part of her career as a molecular epidemiologist at Millennium Pharmaceuticals and in academia, and currently holds adjunct faculty positions at Duke University and the University of California - San Francisco (UCSF). She is the co-author of Precision Medicine: A Guide to Genomics in Clinical Practice, and served as editor-in-chief of Genome, the first magazine dedicated to educating consumers about the promise and challenges of genomic medicine.
Dr. McCarthy is the founder of Precision Medicine Advisors, which brings healthcare organizations, health care providers, diagnostic test developers, health IT companies, investors and others up to speed on the availability, value and limitations of genetic tests on the market and in development.